This review examines the effectiveness of antibody drug conjugates in treating acute myeloid leukemia, indicating their potential impact on future therapies.
Key Points
The aim is to review the role and future prospects of antibody drug conjugates in the treatment of acute myeloid leukemia.
Literature review of existing treatments for AML
Analysis of the mechanistic design of ADCs
Evaluation of clinical trials related to ADCs for AML
Discussion on challenges such as drug resistance and stability
Antibody drug conjugates show promise in treating relapsed and refractory AML cases.
Gemtuzumab ozogamicin is highlighted as an approved ADC for AML.
Challenges like immunogenicity and cost impact ADC effectiveness.
Future advancements may include nanotechnology to enhance ADC delivery.